| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 53 | 2024 | 558 | 9.670 |
Why?
|
| Pleural Neoplasms | 38 | 2024 | 485 | 6.950 |
Why?
|
| Lung Neoplasms | 92 | 2024 | 12033 | 4.470 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 57 | 2024 | 5574 | 3.320 |
Why?
|
| Quinazolines | 14 | 2022 | 956 | 1.760 |
Why?
|
| Pemetrexed | 7 | 2019 | 100 | 1.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 33 | 2024 | 16689 | 1.370 |
Why?
|
| Cisplatin | 11 | 2020 | 2497 | 1.140 |
Why?
|
| Immunotherapy | 11 | 2024 | 3557 | 1.010 |
Why?
|
| Biomarkers, Tumor | 21 | 2024 | 10708 | 0.990 |
Why?
|
| Antineoplastic Agents | 23 | 2023 | 14617 | 0.970 |
Why?
|
| ErbB Receptors | 11 | 2024 | 2375 | 0.970 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 3 | 2014 | 153 | 0.890 |
Why?
|
| Radiotherapy, Intensity-Modulated | 9 | 2022 | 2178 | 0.830 |
Why?
|
| Clinical Trials as Topic | 12 | 2020 | 3844 | 0.790 |
Why?
|
| Gene Dosage | 4 | 2014 | 823 | 0.780 |
Why?
|
| Pneumonectomy | 10 | 2021 | 862 | 0.770 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2020 | 5593 | 0.740 |
Why?
|
| Pyrimidines | 10 | 2024 | 3669 | 0.700 |
Why?
|
| Humans | 142 | 2024 | 270740 | 0.680 |
Why?
|
| Precision Medicine | 6 | 2016 | 1207 | 0.660 |
Why?
|
| Dasatinib | 3 | 2020 | 881 | 0.640 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2022 | 259 | 0.610 |
Why?
|
| Indoles | 7 | 2024 | 1028 | 0.590 |
Why?
|
| Germ-Line Mutation | 4 | 2024 | 1101 | 0.570 |
Why?
|
| Exons | 7 | 2022 | 1383 | 0.550 |
Why?
|
| Aged | 65 | 2024 | 73333 | 0.550 |
Why?
|
| Middle Aged | 68 | 2024 | 90352 | 0.540 |
Why?
|
| Molecular Targeted Therapy | 6 | 2019 | 2399 | 0.540 |
Why?
|
| Carcinogenesis | 3 | 2019 | 1033 | 0.520 |
Why?
|
| Head and Neck Neoplasms | 5 | 2013 | 4147 | 0.510 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2021 | 1335 | 0.510 |
Why?
|
| Mutation | 19 | 2024 | 15912 | 0.500 |
Why?
|
| Male | 74 | 2024 | 128315 | 0.480 |
Why?
|
| Neoadjuvant Therapy | 10 | 2024 | 5231 | 0.470 |
Why?
|
| Female | 75 | 2024 | 148940 | 0.440 |
Why?
|
| Cytidine | 1 | 2013 | 24 | 0.440 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2023 | 417 | 0.430 |
Why?
|
| Neovascularization, Pathologic | 2 | 2019 | 1586 | 0.430 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2020 | 10400 | 0.420 |
Why?
|
| Piperazines | 5 | 2013 | 2145 | 0.410 |
Why?
|
| Survival Rate | 17 | 2021 | 12541 | 0.400 |
Why?
|
| Ipilimumab | 6 | 2023 | 764 | 0.400 |
Why?
|
| Antimitotic Agents | 1 | 2011 | 8 | 0.400 |
Why?
|
| Treatment Outcome | 29 | 2024 | 33737 | 0.390 |
Why?
|
| Neoplasm Staging | 20 | 2023 | 14012 | 0.390 |
Why?
|
| Disease-Free Survival | 17 | 2017 | 10265 | 0.380 |
Why?
|
| Piperidines | 2 | 2013 | 1100 | 0.360 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2013 | 340 | 0.360 |
Why?
|
| Societies, Medical | 1 | 2016 | 1320 | 0.360 |
Why?
|
| Aged, 80 and over | 30 | 2024 | 30998 | 0.350 |
Why?
|
| Hypopigmentation | 2 | 2004 | 26 | 0.340 |
Why?
|
| Tea | 1 | 2009 | 46 | 0.340 |
Why?
|
| Adenocarcinoma | 7 | 2015 | 7914 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2023 | 4961 | 0.330 |
Why?
|
| Phytotherapy | 1 | 2009 | 101 | 0.330 |
Why?
|
| Mitosis | 1 | 2011 | 681 | 0.330 |
Why?
|
| Pleura | 3 | 2021 | 130 | 0.320 |
Why?
|
| Prognosis | 18 | 2022 | 22505 | 0.320 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2022 | 2271 | 0.320 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2013 | 2617 | 0.310 |
Why?
|
| B7-H1 Antigen | 5 | 2024 | 1089 | 0.310 |
Why?
|
| National Cancer Institute (U.S.) | 5 | 2020 | 218 | 0.310 |
Why?
|
| Pleural Effusion, Malignant | 2 | 2009 | 159 | 0.300 |
Why?
|
| Medical Oncology | 1 | 2016 | 1465 | 0.300 |
Why?
|
| Erlotinib Hydrochloride | 6 | 2018 | 398 | 0.300 |
Why?
|
| CTLA-4 Antigen | 2 | 2024 | 678 | 0.300 |
Why?
|
| Plant Extracts | 1 | 2009 | 221 | 0.290 |
Why?
|
| Adult | 43 | 2024 | 82040 | 0.290 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 274 | 0.290 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2024 | 1336 | 0.290 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2022 | 4000 | 0.280 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 678 | 0.280 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2007 | 99 | 0.280 |
Why?
|
| Acrylamides | 2 | 2024 | 68 | 0.280 |
Why?
|
| Papillomaviridae | 1 | 2010 | 636 | 0.280 |
Why?
|
| Thoracic Neoplasms | 3 | 2019 | 363 | 0.280 |
Why?
|
| Carbamates | 2 | 2024 | 81 | 0.270 |
Why?
|
| Combined Modality Therapy | 11 | 2019 | 9039 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 2400 | 0.270 |
Why?
|
| Aniline Compounds | 3 | 2024 | 206 | 0.260 |
Why?
|
| Imatinib Mesylate | 5 | 2013 | 1691 | 0.250 |
Why?
|
| Gene Expression Profiling | 4 | 2014 | 5149 | 0.250 |
Why?
|
| Neoplasm Metastasis | 7 | 2024 | 5315 | 0.250 |
Why?
|
| Proton Therapy | 4 | 2020 | 1637 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2004 | 484 | 0.250 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2004 | 2635 | 0.240 |
Why?
|
| Benzamides | 5 | 2013 | 1879 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2018 | 6256 | 0.230 |
Why?
|
| Mouth Neoplasms | 1 | 2009 | 734 | 0.230 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2024 | 118 | 0.230 |
Why?
|
| Asbestos | 3 | 2019 | 37 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2020 | 3409 | 0.220 |
Why?
|
| Benzimidazoles | 2 | 2024 | 437 | 0.220 |
Why?
|
| Hydrolases | 1 | 2024 | 132 | 0.220 |
Why?
|
| Professionalism | 1 | 2024 | 57 | 0.220 |
Why?
|
| Thiazoles | 1 | 2007 | 723 | 0.210 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 1059 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2024 | 5408 | 0.210 |
Why?
|
| Bronchial Neoplasms | 1 | 2003 | 82 | 0.210 |
Why?
|
| Salvage Therapy | 3 | 2019 | 2123 | 0.210 |
Why?
|
| Enzyme Inhibitors | 2 | 2004 | 1942 | 0.200 |
Why?
|
| Taxoids | 4 | 2017 | 1015 | 0.200 |
Why?
|
| Anticarcinogenic Agents | 1 | 2004 | 368 | 0.200 |
Why?
|
| Papillomavirus Infections | 1 | 2010 | 999 | 0.190 |
Why?
|
| Genes, erbB | 1 | 2021 | 27 | 0.190 |
Why?
|
| Niacinamide | 2 | 2013 | 428 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 7 | 2024 | 4481 | 0.190 |
Why?
|
| Cell Cycle | 1 | 2007 | 2137 | 0.190 |
Why?
|
| Melanoma | 3 | 2023 | 5595 | 0.190 |
Why?
|
| Bevacizumab | 5 | 2019 | 967 | 0.190 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2018 | 164 | 0.190 |
Why?
|
| Gene Amplification | 2 | 2014 | 766 | 0.180 |
Why?
|
| Double-Blind Method | 7 | 2022 | 2580 | 0.180 |
Why?
|
| United States | 12 | 2024 | 15861 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2024 | 1903 | 0.180 |
Why?
|
| Spouses | 2 | 2020 | 140 | 0.170 |
Why?
|
| Polyethylene Glycols | 1 | 2024 | 654 | 0.170 |
Why?
|
| Proportional Hazards Models | 5 | 2022 | 5101 | 0.170 |
Why?
|
| Radiation Dosage | 2 | 2022 | 1042 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 282 | 0.170 |
Why?
|
| Mindfulness | 1 | 2020 | 56 | 0.170 |
Why?
|
| Cell Movement | 1 | 2007 | 2472 | 0.170 |
Why?
|
| Phenylurea Compounds | 2 | 2013 | 600 | 0.170 |
Why?
|
| Azepines | 1 | 2020 | 134 | 0.170 |
Why?
|
| Consensus | 3 | 2019 | 1106 | 0.170 |
Why?
|
| Radiology, Interventional | 1 | 2020 | 142 | 0.160 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 383 | 0.160 |
Why?
|
| Smoking | 2 | 2019 | 2555 | 0.160 |
Why?
|
| Neoplasms | 5 | 2022 | 15927 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 153 | 0.160 |
Why?
|
| Patient Safety | 1 | 2024 | 613 | 0.160 |
Why?
|
| Quality of Life | 8 | 2022 | 4761 | 0.150 |
Why?
|
| Transcription Factors, TFII | 1 | 2018 | 23 | 0.150 |
Why?
|
| Treatment Refusal | 1 | 2019 | 128 | 0.150 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2018 | 18 | 0.150 |
Why?
|
| Ubiquitin Thiolesterase | 4 | 2022 | 225 | 0.150 |
Why?
|
| Dyspnea | 2 | 2022 | 420 | 0.150 |
Why?
|
| Mind-Body Therapies | 1 | 2017 | 29 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 2651 | 0.150 |
Why?
|
| Cohort Studies | 6 | 2021 | 9470 | 0.140 |
Why?
|
| Survival Analysis | 6 | 2014 | 9292 | 0.140 |
Why?
|
| Radiation Injuries | 3 | 2014 | 1471 | 0.140 |
Why?
|
| Sulfonamides | 2 | 2024 | 1933 | 0.140 |
Why?
|
| ras Proteins | 3 | 2013 | 804 | 0.140 |
Why?
|
| Chemoradiotherapy | 4 | 2022 | 2027 | 0.140 |
Why?
|
| Retrospective Studies | 14 | 2024 | 39890 | 0.140 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2008 | 73 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2013 | 2313 | 0.140 |
Why?
|
| Vaccines, Subunit | 1 | 2017 | 128 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 7783 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 1097 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 5776 | 0.130 |
Why?
|
| Re-Irradiation | 1 | 2017 | 166 | 0.130 |
Why?
|
| Dexamethasone | 2 | 2022 | 1516 | 0.130 |
Why?
|
| Tumor Burden | 2 | 2021 | 2033 | 0.130 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 550 | 0.130 |
Why?
|
| Image-Guided Biopsy | 2 | 2020 | 336 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 637 | 0.130 |
Why?
|
| Leukemia | 1 | 2004 | 1719 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 2 | 2021 | 1322 | 0.120 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 510 | 0.120 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2017 | 340 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2013 | 1402 | 0.120 |
Why?
|
| Lung | 4 | 2020 | 3298 | 0.120 |
Why?
|
| Thymoma | 1 | 2018 | 252 | 0.120 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2014 | 30 | 0.120 |
Why?
|
| Apoptosis | 2 | 2014 | 7757 | 0.120 |
Why?
|
| Radiation Pneumonitis | 1 | 2016 | 313 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 695 | 0.110 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 15218 | 0.110 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2013 | 109 | 0.110 |
Why?
|
| Genomics | 5 | 2024 | 2835 | 0.110 |
Why?
|
| Glutamates | 1 | 2013 | 134 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2018 | 517 | 0.110 |
Why?
|
| Disease Management | 1 | 2019 | 1090 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1312 | 0.110 |
Why?
|
| Lipocalins | 1 | 2013 | 54 | 0.110 |
Why?
|
| Interleukin-9 | 1 | 2013 | 37 | 0.110 |
Why?
|
| Induction Chemotherapy | 2 | 2017 | 670 | 0.110 |
Why?
|
| Guanine | 1 | 2013 | 157 | 0.110 |
Why?
|
| Placebos | 2 | 2015 | 442 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2013 | 85 | 0.110 |
Why?
|
| Lipocalin-2 | 1 | 2013 | 77 | 0.110 |
Why?
|
| Genes, erbB-1 | 1 | 2013 | 104 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 451 | 0.110 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 416 | 0.100 |
Why?
|
| Microtubules | 1 | 2014 | 329 | 0.100 |
Why?
|
| Genes, myc | 1 | 2014 | 371 | 0.100 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 210 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 334 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 454 | 0.100 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2012 | 114 | 0.100 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 84 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2024 | 3949 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2019 | 1857 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2011 | 77 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 1174 | 0.100 |
Why?
|
| Postoperative Complications | 4 | 2021 | 5681 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 126 | 0.090 |
Why?
|
| Patient Selection | 2 | 2017 | 2025 | 0.090 |
Why?
|
| Risk Factors | 5 | 2019 | 17888 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 1269 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 477 | 0.090 |
Why?
|
| Sirolimus | 1 | 2015 | 831 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 3597 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 1557 | 0.090 |
Why?
|
| Carcinosarcoma | 1 | 2011 | 145 | 0.090 |
Why?
|
| Feasibility Studies | 3 | 2016 | 2353 | 0.080 |
Why?
|
| Neoplasm Seeding | 1 | 2009 | 66 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2011 | 1608 | 0.080 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 4895 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1189 | 0.080 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 206 | 0.080 |
Why?
|
| Genes, ras | 1 | 2012 | 679 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2013 | 12103 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2014 | 617 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 4960 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2009 | 927 | 0.070 |
Why?
|
| Adolescent | 6 | 2023 | 32767 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2004 | 382 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2020 | 2828 | 0.070 |
Why?
|
| Radiotherapy Dosage | 4 | 2020 | 4019 | 0.070 |
Why?
|
| Polyethylenes | 2 | 1997 | 14 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 1580 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 284 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2019 | 2250 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 661 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2014 | 6390 | 0.070 |
Why?
|
| Biocompatible Materials | 2 | 1997 | 202 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2011 | 898 | 0.060 |
Why?
|
| Disease Progression | 4 | 2020 | 6867 | 0.060 |
Why?
|
| American Cancer Society | 1 | 2024 | 35 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2014 | 14849 | 0.060 |
Why?
|
| Oligopeptides | 2 | 1997 | 450 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 5923 | 0.060 |
Why?
|
| CD13 Antigens | 1 | 2004 | 43 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2014 | 9042 | 0.060 |
Why?
|
| Cell Adhesion | 2 | 1997 | 1028 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 5056 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2007 | 1810 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 262 | 0.060 |
Why?
|
| Topotecan | 1 | 2004 | 248 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 4048 | 0.050 |
Why?
|
| Time Factors | 3 | 2024 | 13006 | 0.050 |
Why?
|
| Phenotype | 1 | 2014 | 6509 | 0.050 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 7655 | 0.050 |
Why?
|
| Young Adult | 4 | 2018 | 22251 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2004 | 251 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2024 | 500 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 640 | 0.050 |
Why?
|
| Respiratory Mucosa | 1 | 2003 | 212 | 0.050 |
Why?
|
| Anesthesiology | 1 | 2024 | 146 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3035 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2020 | 13414 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2004 | 4942 | 0.050 |
Why?
|
| Carcinoma | 1 | 2013 | 2610 | 0.050 |
Why?
|
| Bronchi | 1 | 2003 | 325 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 4963 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3077 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 3339 | 0.050 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2001 | 9 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 2069 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2014 | 2887 | 0.050 |
Why?
|
| Epithelium | 1 | 2003 | 782 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2009 | 1716 | 0.050 |
Why?
|
| Arginine | 1 | 2024 | 507 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2024 | 1126 | 0.040 |
Why?
|
| Carboplatin | 2 | 2016 | 880 | 0.040 |
Why?
|
| Implants, Experimental | 2 | 1997 | 21 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2014 | 1430 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2021 | 219 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2021 | 205 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2003 | 481 | 0.040 |
Why?
|
| Registries | 2 | 2018 | 2211 | 0.040 |
Why?
|
| Polymers | 1 | 2001 | 222 | 0.040 |
Why?
|
| Foundations | 1 | 2019 | 22 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 30 | 0.040 |
Why?
|
| Inhalation Exposure | 1 | 2019 | 46 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 108 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 75 | 0.040 |
Why?
|
| Protein Methyltransferases | 1 | 2018 | 46 | 0.040 |
Why?
|
| Australia | 1 | 2019 | 259 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 565 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 338 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 483 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 1121 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2021 | 426 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2020 | 250 | 0.040 |
Why?
|
| Pneumonia | 2 | 2017 | 796 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 550 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 1246 | 0.040 |
Why?
|
| Legislation, Drug | 1 | 2018 | 13 | 0.040 |
Why?
|
| Alveolar Bone Loss | 1 | 1997 | 7 | 0.040 |
Why?
|
| Metacarpus | 1 | 1997 | 7 | 0.040 |
Why?
|
| Gingiva | 1 | 1997 | 19 | 0.040 |
Why?
|
| Alveolar Process | 1 | 1997 | 10 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 699 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1824 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 325 | 0.040 |
Why?
|
| Palliative Care | 1 | 2009 | 2178 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 4328 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 658 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2019 | 248 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 1379 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1997 | 94 | 0.040 |
Why?
|
| Polylysine | 1 | 1997 | 19 | 0.040 |
Why?
|
| Menopause | 1 | 1997 | 160 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2017 | 103 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 689 | 0.040 |
Why?
|
| Foreign-Body Reaction | 1 | 1997 | 31 | 0.030 |
Why?
|
| Research Design | 2 | 2017 | 1569 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2003 | 1710 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2015 | 1563 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2021 | 738 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 1 | 2017 | 227 | 0.030 |
Why?
|
| Spirituality | 1 | 2017 | 129 | 0.030 |
Why?
|
| Saliva | 1 | 1997 | 238 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 3216 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1726 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 448 | 0.030 |
Why?
|
| Sleep Stages | 1 | 2016 | 82 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 739 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 867 | 0.030 |
Why?
|
| Spirometry | 1 | 2016 | 153 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 861 | 0.030 |
Why?
|
| Osteopontin | 1 | 2016 | 145 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 226 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1032 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 460 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2017 | 419 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 2453 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 823 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 5759 | 0.030 |
Why?
|
| Recurrence | 1 | 2023 | 4878 | 0.030 |
Why?
|
| Bone Density | 1 | 1997 | 466 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 518 | 0.030 |
Why?
|
| Age Factors | 1 | 2004 | 5457 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1291 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 283 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 1137 | 0.030 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 65 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 372 | 0.030 |
Why?
|
| Epothilones | 1 | 2014 | 55 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 772 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2016 | 290 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1690 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2016 | 397 | 0.030 |
Why?
|
| Caregivers | 1 | 2020 | 752 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2019 | 6764 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 1754 | 0.030 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2014 | 231 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1997 | 1050 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 329 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2004 | 1903 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2394 | 0.030 |
Why?
|
| Everolimus | 1 | 2015 | 436 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2014 | 6224 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1655 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 757 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2359 | 0.020 |
Why?
|
| Genome, Human | 1 | 2020 | 1888 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 2009 | 4567 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2014 | 501 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 324 | 0.020 |
Why?
|
| Biomarkers | 1 | 2003 | 5051 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2012 | 136 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 2431 | 0.020 |
Why?
|
| Valine | 1 | 2012 | 180 | 0.020 |
Why?
|
| Lentivirus | 1 | 2012 | 164 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1075 | 0.020 |
Why?
|
| Cysteine | 1 | 2012 | 214 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2014 | 728 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 396 | 0.020 |
Why?
|
| Mediastinum | 1 | 2012 | 276 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2017 | 1043 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 589 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2020 | 2457 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 895 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 625 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1199 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2013 | 743 | 0.020 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2009 | 26 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 2650 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4831 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2009 | 82 | 0.020 |
Why?
|
| Esophagitis | 1 | 2011 | 210 | 0.020 |
Why?
|
| Glycine | 1 | 2012 | 322 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 1271 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2009 | 6177 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5824 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 690 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3345 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 3707 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 2315 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 62 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 2357 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 3584 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 2471 | 0.020 |
Why?
|
| Animals | 3 | 2024 | 61956 | 0.020 |
Why?
|
| Protons | 1 | 2011 | 481 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 1082 | 0.020 |
Why?
|
| Depression | 1 | 2017 | 1730 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 1470 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 722 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 5866 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 1838 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 1857 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 1472 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 3640 | 0.020 |
Why?
|
| Proteome | 1 | 2009 | 571 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4372 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 2115 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 1963 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 1005 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2009 | 1474 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2009 | 2090 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2011 | 2101 | 0.010 |
Why?
|
| Mice | 1 | 2024 | 35600 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 572 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2009 | 1005 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 3438 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 6685 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 1437 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2003 | 231 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2014 | 7238 | 0.010 |
Why?
|
| Colorimetry | 1 | 2001 | 31 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 3194 | 0.010 |
Why?
|
| Microspheres | 1 | 2001 | 237 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2001 | 600 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 16215 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1997 | 318 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1997 | 316 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2003 | 1388 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1997 | 2156 | 0.010 |
Why?
|
| Cell Survival | 1 | 1997 | 3063 | 0.010 |
Why?
|
| Macrophages | 1 | 1997 | 1350 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 5694 | 0.000 |
Why?
|
| Rats | 1 | 1997 | 6441 | 0.000 |
Why?
|
| Cytokines | 1 | 1997 | 2825 | 0.000 |
Why?
|